Levine A B, Teppa J, McGough B, Cowchock F S
Department of Obstetrics and Gynecology, Jefferson Medical College, Philadelphia, PA 19107, USA.
Contraception. 1996 May;53(5):255-7.
The purpose of this study was to determine the effects of pregnancy and oral contraceptive use on in vivo coagulation by measurement of plasma levels of prothrombin fragment 1 + 2 and thrombin antithrombin III complex. Fifty-four women with uncomplicated singleton gestations, 34 women using oral contraceptives and 45 non-pregnant controls were the subjects of this study. Levels of prothrombin fragment 1 + 2 and thrombin-antithrombin III complex were measured using enzyme linked immunoassays. In uncomplicated pregnancies, levels of prothrombin fragment 1 + 2 and thrombin antithrombin III complex increased significantly with advancing gestational age. Women using oral contraceptives had significantly higher levels of prothrombin fragment 1 + 2 and thrombin antithrombin III complex compared to non-pregnant controls. The significant increase in levels of prothrombin fragment 1 + 2 and thrombin-antithrombin III complex throughout gestation and in women using oral contraceptives provided evidence of thrombin activation during these clinical conditions.
本研究的目的是通过测量血浆凝血酶原片段1+2和凝血酶抗凝血酶III复合物的水平，确定妊娠和口服避孕药对体内凝血的影响。54例单胎妊娠无并发症的女性、34例使用口服避孕药的女性和45例非妊娠对照者是本研究的对象。使用酶联免疫分析法测量凝血酶原片段1+2和凝血酶-抗凝血酶III复合物的水平。在无并发症的妊娠中，凝血酶原片段1+2和凝血酶抗凝血酶III复合物的水平随着孕周的增加而显著升高。与非妊娠对照者相比，使用口服避孕药的女性凝血酶原片段1+2和凝血酶抗凝血酶III复合物的水平显著更高。在整个妊娠期以及使用口服避孕药的女性中，凝血酶原片段1+2和凝血酶-抗凝血酶III复合物水平的显著升高提供了在这些临床情况下凝血酶激活的证据。
